

# Orange Book Stories

Michael Risch

Professor of Law

Villanova University Charles Widger School of Law

# The challenge

- Saying something new about Orange Book patenting
  - Lots of great papers out there
  - Lots of great data out there
- Finding Recent data
  - No two papers seem to use the same data
  - Even the best data sets are outdated
  - PatEx stops in 2022, which means losing years of granted patents and new applications

# The Solution – update it all

- Step 1 – Build the full Orange Book list
- Step 2 – Update PatEx
- Step 3 – Find something interesting and new to say

# Step 1 – Building the Orange Book List the lazy scholar's way

- Grab all the patents listed in the NBER Orange Book database (~5500)
  - This is very good on the older patents, but stops in 2016
- Grab all the patents listed as Orange Book in Lexis Total Patent One (~9950)
  - This is very good on newer patents, but is missing many older patents
- Join the two
- Current total ~11,000 Orange Book patents

## Step 2: Extending PatEx – the not so lazy way



- Download bulk Patent File Wrapper data from PTO (JSON format)
- Develop streaming JSON reader to convert each application record into several CSV files with unique key
- Import CSV files into Stata and format variables to match PatEx Database
- Merge imported files into PatEx, updating existing records and adding new
  - e.g. add issued patents, new parents, new children
  - e.g. add new applications that were not published as of 2023 PatEx release
- Rinse and repeat for each year, testing to see whether changes justify the time
- Final tally: Added updated records from 2018-2025 to system
  - 2019 added 13,000 new patents, nearly 20% of applications
  - 2018 added only 2,000 new patents, good enough for me
  - 300 of 11000 OB patents still missing from updated PatEx
    - Will likely import <2017 at some point

Step 3 – Anything interesting?


# Key difference from other studies

- This study is based on patent families, not drugs
  - ~4700 families <> number of drugs
- There could be single families that apply to multiple Orange Book entries
- There could be multiple families that apply to single Orange Book entries
- Dates will not match
  - Most studies use approval date
  - This study uses filing and grant dates, which can be offset one way or the other
- Nonetheless, a cursory comparison to other papers shows that the trends are the same over similar time periods



## Orange Book Patenting by year of earliest patent issue date



## Orange Book Patenting by year of earliest patent issue date





# Patent Pendency by year of filing




includes both listed and unlisted patents

# Orange Book Patenting


by year of earliest application filing




## Orange Book Patenting by year of earliest application filing



## Orange Book Patenting by year of earliest application filing




Orange Book Patents




Orange Book Terminal Disclaimers

## Orange Book Patents by Year

by earliest application filing date




# Hemphill & Sampat 2011




# Orange Book Patents by Year

by earliest application filing date




Median Orange Book Patents



Median All Patents


## Orange Book Patents by Year

by earliest product approval date




## Orange Book Patents by Year

by earliest product approval date




## Family Patent Filings by Final Year of Application

for all pre-URAA applications



## Mean Life of Patent Families by Filing and Grant for all pre-URAA applications



- Mean Days Between First and Last Patent Issued
- - - - Mean Days Between First and Last Application Filing
- Count of Patent Families with Final Application in Year

# Inventor Overlap

	Frequency	Percent
All Inventors The Same		
0	1,883	48.51%
1	1,999	51.49%
Total	3,882	100.00%

	Frequency	Percent
Some Overlap Among All Patents		
0	426	10.97%
1	3,456	89.03%
Total	3,882	100.00%

# Sanity Check

## Hypocalcaemic Peptides And Process For Their Manufacture

DOCUMENT ID		DATE PUBLISHED	
US 4347242 A		1982-08-31	
INVENTOR INFORMATION			
NAME	CITY	STATE	ZIP CO
Neher; Robert	Binningen	N/A	N/A
Riniker; Bernhard	Frenkendorf	N/A	N/A
ASSIGNEE INFORMATION			
NAME	CITY	STATE	ZIP CO
Ciba-Geigy Corporation	Ardsley	NY	N/A
TYPE CODE			
02			
APPLICATION NO		DATE FILED	
05/889066		1978-03-22	

## Hypocalcaemic Peptides And Process For Their Manufacture

DOCUMENT ID		DATE PUBLISHED			
US RE32347 E		1987-02-03			
INVENTOR INFORMATION					
NAME		CITY	STATE	ZIP CODE	COUNTRY
Neher; Robert		Binningen	N/A	N/A	CH
Riniker; Bernhard		Frenkendorf	N/A	N/A	CH
ASSIGNEE INFORMATION					
NAME		CITY	STATE	ZIP CODE	COUNTRY
Ciba-Geigy Corp.		Ardsley	NY	N/A	N/A
TYPE CODE					
02					
APPLICATION NO		DATE FILED			
06/644696		1984-08-27			

# Sanity Check

**PCT#**

PCT/US13/23312

## **Inventors**

---

JOHN JOSEPH FEENEY  
OLNEY, MARYLAND (US)

MARLENE MICHELLE DRESSMAN  
GERMANTOWN, MARYLAND (US)

MIHAEL H. POLYMEROPOULOS  
POTOMAC, MARYLAND (US)

LOUIS WILLIAM LICAMELE  
POTOMAC, MARYLAND (US)

**PCT#**

PCT/US13/23315

## **Inventors**

---

LOUIS WILLIAM LICAMELE  
POTOMAC, MARYLAND (US)

MIHAEL H. POLYMEROPOULOS  
POTOMAC, MARYLAND (US)

MARLENE MICHELLE DRESSMAN  
GERMANTOWN, MARYLAND (US)

# Sanity Check

## Application #

16/387,504

## Inventors

---

Sean Cunningham  
Athlone (IE)

Seamus Mulligan  
Athlone (IE)

Michael Myers  
Broadlands, VIRGINIA (US)

## Application #

17/831,209

## Inventors

---

Andrew R. Blight  
Old Saybrook, CONNECTICUT (US)

Ron Cohen  
Irvington, NEW YORK (US)

## Applicants

---

Alkermes Pharma Ireland Limited  
Dublin (IE)


## Applicants

---


Acorda Therapeutics, Inc.  
Ardsley

# Inventor Overlap by Family Size

capped at 3000 for illustration



## Use of Provisional Applications by Family



x Percent Provisionals Per Family

● Percent of Families Including Provisional

----- Fitted values

# Possible next steps

- Break down by product?
  - Challenge: substantial patent overlap
- Does family size deter generic entry/ANDA litigation?
  - Challenge: timing of patents v. timing of litigation
  - Challenge: including sales (see, e.g. Hemphill & Sampat 2011)
- Did 2003 changes to listing rules affect listing volume?
- Timing analysis – are patents expiring later?
  - Challenge – comparing families withing NDA grouping
- Compare with litigation and IPR outcomes
  - Cf. Tu & Lemley
- Other stuff?